- Research note
- Open Access
“It wasn’t as bad as I thought it would be”: a qualitative study of early stage non-small cell lung cancer patients after treatment
BMC Research Notes volume 10, Article number: 642 (2017)
While surgical resection is recommended for most patients with early stage lung cancer, stereotactic body radiotherapy (SBRT) is being increasingly utilized. Provider-patient communication regarding risks/benefits of each approach may be a modifiable factor leading to improved patient-centered outcomes. Our objective was to determine a framework and recommended strategies on how to best communicate with patients with early stage non-small cell lung cancer (NSCLC) in the post-treatment setting. We qualitatively evaluated the experiences of 11 patients with early clinical stage NSCLC after treatment, with a focus on treatment experience, knowledge obtained, communication, and recommendations. We used conventional content analysis and a patient-centered communication theoretical model to guide our understanding.
Five patients received surgery and six received SBRT. Both treatments were generally well-tolerated. Few participants reported communication deficits around receiving follow-up information, although several had remaining questions about their treatment outcome (mainly those who underwent SBRT). They described feeling anxious regarding their first surveillance CT scan and clinician visit. Overall, participants remained satisfied with care because of implicit trust in their clinicians rather than explicit communication. Communication gaps remain but may be addressed by a trusting relationship with the clinician. Patients recommend clinicians give thorough explanations and personalize when possible.
With the advent of lung cancer screening, more people will be diagnosed with early stage disease . Surgery is the recommended therapy for stage I non-small cell lung cancer (NSCLC) [2, 3] although stereotactic body radiotherapy (SBRT) is increasingly utilized. SBRT is typically performed in individuals who either refuse or cannot tolerate surgery [3, 4]. Nonetheless, SBRT may become an equivalent or potentially even better option since, in a limited trial, patients who were treated with SBRT had lower mortality and better global health-related quality of life (HR-QOL) 3.5 years after treatment than patients treated with surgery . There are currently little data regarding how clinicians or patients make decisions about these two treatments for early stage lung cancer, and no data on decision making strategies that patients prefer to utilize. It is important to determine the best way to communicate with patients with early stage lung cancer about post-treatment procedures since communication may be one of only a few modifiable factors that could improve health outcomes.
To our knowledge, the current analysis represents the first prospective qualitative comparison and contrast assessment of the experience of patients who underwent either surgical or radiation treatment for early stage NSCLC, primarily focusing on patient-clinician communication strategies.
We qualitatively evaluated the experiences of patients with clinical stage I NSCLC before treatment, and then at 1 month and 1 year after treatment. The current analysis is based on the two follow-up interviews. We included patients treated at three medical centers in the northwest US: the Veterans Administration Portland Health Care System; Oregon Health & Science University (OHSU); and Legacy Health. We enrolled patients with suspected or confirmed stage I NSCLC being considered for curative treatment during 2014–2015. Pathologic confirmation of lung cancer was not an inclusion criterion . We excluded patients with a history of lung cancer in the past 5 years, those who scored < 17/30 on the St. Louis University Mental Status Examination, had severe hearing impairment, were non-English speaking, lived in a skilled nursing facility, or were diagnosed with psychotic or cognitive disorders. The Joint Internal Review Board of the VA Portland Health Care System and OHSU (#10340), and the Legacy IRB, approved this study. All participants completed written informed consent. We completed recruitment after 13 participants, as we had reached thematic saturation at each study site [7, 8].
Our interview guide allowed for deviations as necessary and included questions about the treatment and post-treatment experience, gaps in knowledge, communication, and perceived barriers and facilitators to high quality care. Participants self-reported demographic and smoking characteristics. Using standardized report forms, we collected diagnosis and treatment information from the electronic medical record.
We used directed content analysis  and ATLAS.ti 7.1.7 (ATLAS.ti GmbH, Berlin, Germany) to organize and analyze the interviews. Each participant is identified by a randomly assigned letter not related to his or her name or treating hospital system, with a letter after a hyphen indicating if they were treated by SBRT (“R”) or surgery (“S”), then ending with a number to indicate if the reference came from the 1 month post-treatment interview (“2”) or the 1 year post-treatment interview (“3”). Individual participants are referred to as “she/her” to protect anonymity.
We used a patient-centered communication (PCC) theoretical model  to guide our understanding of the communication strategies, but the flexibility of the interview guide allowed other themes to emerge. The PCC domains include: information exchange; patient as person (consideration of patients’ feelings, preferences, and values); sharing power and responsibility (shared decision making); therapeutic alliance (the need for patient and provider to be “on the same page”); and clinician as person (Fig. 1) , although only the former three domains are discussed here since the latter two were not fully assessed during the interviews.
Of the initial 13 participants, 11 are discussed herein. Eleven completed the 1 month post-treatment (visit 2) interview, and 10 completed the 1 year post-treatment (visit 3) interview. Most participants were white (82%), former smokers (82%), and female (55%). Table 1 describes participant characteristics. We did not find substantially different themes based on care location.
Patient as person
Both treatments were generally well-tolerated and all participants were pleased with their treatment, care, and current QOL (Table 2). As participant M-R-2 said, “It was bad, but it wasn’t as bad as I thought it would be.” Satisfaction with care was mostly due to implicit trust in their clinicians. Participant G-R-2 exemplified what many expressed, “I totally, thoroughly trust these guys. I mean I just feel like they dedicate so much of their life to learning all of this that I put my money on them and I’m sticking it there!” All participants except one, who received surgery, indicated they would undergo their selected treatment again if necessary.
Post-treatment quality of life
Half of all participants reported increased dyspnea after treatment compared to baseline, regardless of treatment. Most participants felt fatigued 1 month after SBRT treatments which almost completely resolved at 1 year post-treatment. Three participants who underwent surgery had worse dyspnea at 1 month compared to baseline, but by 12 months only one had worse dyspnea compared to baseline while the others improved to pre-treatment levels. The two whose breathing had improved by 12 months were pleasantly surprised, since they reported it was logical to have increased dyspnea from baseline since they had part of their lung removed. Participant H-S-3 explained, “Obviously since I lost a quarter of my lungs that would tend to make me feel shortness of breath.” All participants stated they were told about these possibilities prior to treatment and most expected them.
Few participants reported having remaining questions about their treatment. However, when queried, several reported a lack of knowledge about how and when follow-up would occur, and had remaining questions about their treatment outcome. A number of participants who received SBRT were unsure about the status of their disease and questioned if they were “cured.” These participants described feeling anxious regarding their first surveillance scan. One participant (M-R-3) in particular stated, “And still to this day I’m unsure what my condition is. I don’t know whether it’s metastasized or if I’m in good shape.” Most communication deficits in both groups involved a lack of knowledge regarding the overall follow-up plan (Table 2).
Shared decision making
We asked several questions about the process of shared decision making (SDM) in general and the actual treatment decision. The interviewer(s) frequently had to explain what was meant by the decision making process and gave available options since participants often did not realize a decision was made. Two participants who received surgery felt they had no treatment choice. Participant K-S-2 said, “I wouldn’t say I had any other option other than the surgery,” but nonetheless remained satisfied with the decision making process. Remaining participants felt like they made the decision after getting all of the information they needed.
Almost all participants desired SDM, explaining the ideal decision making process as obtaining all of the facts and options from their clinicians before making their own decision. As participant L-R-2 stated, “I don’t think that would be shared at all [if one person doesn’t participate]. I mean, you’re not sharing if you’re not talking!” Several discussed the importance of both parties being involved in the decision process and that this occurred with their own decision. However, when queried more extensively, their decision making process often did not seem to meet their own definition of SDM. For example, at the baseline interview the participants who were surgical candidates reported clinicians infrequently discussed SBRT with them, which they confirmed at follow-up. Almost all later reported that all patients should hear about all treatment options despite the ability to tolerate surgery since information is a key part of SDM.
Even if SDM did not seem to happen, participants were still very satisfied with the decision making process. Trust in the clinician seemed to be important at explaining this apparent contradiction. Participant M-R-2 indicated, “Well that’s the only reason that I did it [treatment]. I assume that [my doctor] knew what he was doing. That’s all you can do, you know?” see Table 2 for related quotes.
Participant recommendations are in Table 3.
We found that overall, participants were satisfied with their treatment experience and QOL 1 month and 1 year post-treatment. They would almost always select their chosen treatment again. Most participants were very satisfied with the information they received, although many still had knowledge gaps about their treatment outcome and follow-up, especially those who underwent SBRT. Remaining questions and knowledge gaps were not clearly linked to reports of dissatisfaction, likely based on trust in their clinicians. Most participants felt they shared the treatment decision with their clinician. They believed all patients should be told about both treatments regardless of surgical candidacy although most did not feel they themselves received this information.
At the 1 month post-treatment visit, patients who received surgery indicated their QOL was still fairly high and not too different from baseline despite experiencing the expected side effects of surgery. Our findings suggest that future RCTs and observational trials will find worse short-term symptoms but similar QOL for patients undergoing surgery compared to those undergoing SBRT. The treatment experience was similar for both groups, which adds to the growing body of literature describing the possible equipoise between surgery and SBRT .
Participants in our study reported being well-informed about their treatments. Some, though, were unaware of their oncologic outcome (mostly those who underwent SBRT) and were distressed about their first surveillance scan. In other settings, distress is associated with lower adherence [12,13,14,15] so it will be important to evaluate if these patients are less likely to undergo surveillance imaging. The patient-centered communication model suggests that eliciting patients’ worries and concerns can mitigate distress . Even when high quality care is not obtained, trust has been associated with self-reported high quality communication  and satisfaction with care  and high levels of trust are associated with improved adherence . It is possible that trust as well as the positive treatment outcome are more essential than communication for patients with early stage lung cancer. The PCC model also points to other domains of communication that may be important to improving care, such as addressing patients’ values .
Participants did not describe key aspects of SDM like information gathering, discussing patient values and preferences, or developing a partnership . These findings reflected results found in our qualitative study of clinicians, where clinicians confirmed they did not often discuss other treatments or ask about values and preferences directly . Thus, it is not clear if SDM actually occurred had the decision been objectively recorded, despite reports that it did. Participants were still satisfied with the decision making process with little to no regret about their selected treatment. This seeming inconsistency may be due to the difficulty of measuring SDM. More and better quantitative tools are needed to improve consistency across studies . It is important to note that some domains of communication may be associated with improvement in some outcomes but not others. For instance, our findings indicate some domains, like SDM, may be unnecessary for high quality care in certain clinical situations.
In order to address patient-reported communication gaps relating to treatment outcomes and follow-up procedures, clinicians and health care systems may need to develop improved processes or materials to ensure patients receive accurate information and ensure trust. Both treatment options should be discussed openly with all patients, despite their ability to tolerate surgery, explanations should be thorough, and personalized.
We included participants from three health care settings in the Pacific Northwest so results may not be generalizable.
Patient and clinician personal characteristics may influence perceptions of care and recall.
We did not directly observe patient-clinician interactions so findings may not reflect actual practices, although the results are mirrored by our interviews with clinicians .
Our results are subject to participant recall bias, as well as moderator acceptance bias .
health-related quality of life
non-small cell lung cancer
Oregon Health & Science University
stereotactic body radiotherapy
shared decision making
Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Intern Med. 2013;159:411–20.
Liu Y, Huang C, Liu H, Chen Y, Li S. Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study. World J Surg Oncol. 2014;12:1–6.
Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e1S–29S.
Wood DE. National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin. 2015;25:185–97.
Louie AV, van Werkhoven E, Chen H, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: results from the ROSEL multicenter randomized trial. Radiother Oncol. 2015;117:44–8.
Rutter CE, Corso CD, Park HS, et al. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States. Lung Cancer. 2014;85:390–4.
Patton M. Designing qualitative studies. In: Qualitative research & evaluation methods. 3rd ed. Thousand Oaks: Sage Publications; 2002. p. 209.
Pope C, Ziebland S, Mays N. Analysing qualitative data. In: Pope C, Mays N, editors. Qualitative research in health care. 3rd ed. Malden: Blackwell Publishing; 2006. p. 63.
Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277–88.
Street RL, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician patient communication to health outcomes. Patient Educ Couns. 2009;74:295–301.
Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51:1087–110.
Lerman CE, Rimer BK. Psychosocial impact of cancer screening. Oncology. 1993;7:67–72 (discussion 72, 75, 79).
O’Donnell S, Goldstein B, Dimatteo MR, Fox SA, John CR, Obrzut JE. Adherence to mammography and colorectal cancer screening in women 50–80 years of age the role of psychological distress. Womens Health Issues. 2010;20:343–9.
Moseson EM, Wiener RS, Golden SE, et al. Patient and clinician characteristics associated with adherence. A cohort study of veterans with incidental pulmonary nodules. Ann Am Thorac Soc. 2016;13:651–9.
Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178:826–31 (discussion 831–2).
Nicolai J, Buchholz A, Seefried N, et al. When do cancer patients regret their treatment decision? A path analysis of the influence of clinicians’ communication styles and the match of decision-making styles on decision regret. Patient Educ Couns. 2016;99:739–46.
Golden SE, Thomas CR Jr, Deffebach ME, et al. “Even if I don’t remember, I feel better”: a qualitative study of early stage non-small cell lung cancer patients undergoing stereotactic body radiotherapy or surgery. Ann Am Thorac Soc. 2016;13(8):1361–9.
Hillen MA, de Haes HC, Smets EM. Cancer patients’ trust in their physician—a review. Psychooncology. 2011;20:227–41.
Towle A, Godolphin W, Grams G, LaMarre A. Putting informed and shared decision making into practice. Health Expect. 2006;9:321–32.
Golden SE, Thomas CR Jr, Moghanaki D, Slatore CG, Early Stage Lung Cancer Comparative Effectiveness Research Consortium. Dumping the information bucket: a qualitative study of clinicians caring for patients with early stage non-small cell lung cancer. Patient Educ Couns. 2016;100(5):861–70.
Scholl I, Loon MK, Sepucha K, et al. Measurement of shared decision making: a review of instruments. Z Evid Fortbild Qual Gesundh wesen. 2011;105:313–24.
Hoets H. Focus group tips. http://www.focusgrouptips.com/qualitative-research.html. Accessed 6 June 2014.
SEG, CRT, MED, MSS, PHS, BHT, AYK, ACT, CGS have made substantial contributions to the (1) conception and design, acquisition of data, or analysis and interpretation of data; (2) have contributed to drafting the article for important intellectual content; and (3) have provided final approval of the version to be published. SEG takes responsibility for the content of the manuscript, including data and analysis. This manuscript represents original work and is not under consideration for publication elsewhere. SEG, CRT, MED, MSS, PHS, BHT, AYK, ACT, CGS meet the criteria for authorship and will sign a statement attesting authorship, disclosing all potential competing interests, and releasing the copyright should the manuscript be accepted for publication. We have conformed to all journal requirements. All authors read and approved the final manuscript.
Writing Committee Members for The Early Stage Lung Cancer Comparative Effectiveness Research Consortium
We thank these members for their contribution to the collection of data and support of the study.
Lead Site Investigators VA Portland Health Care System Mark E. Deffebach, MD, Mithran S. Sukumar, MD, Oregon Health & Science University Paul H. Schipper, MD, Brandon H. Tieu, MD, Charles R. Thomas Jr., MD, Charlotte D. Kubicky, MD, Ph.D., John M. Holland, MD, MS, Legacy Health System Andrew Y. Kee, MD, Andrew C. Tsen, MD, Providence Health & Services John R. Handy Jr., MD, Hon.D, Steven Seung, MD, Ph.D., FACR, PeaceHealth Southwest Washington Medical Center Michael A. Myers, MD, Dennis L. Febinger, MD, Tuality Healthcare Timur Mitin, MD, Ph.D., Srinivas R. Mummadi, MD, FCCP, Kaiser Permanente Kelli D. Salter, MD, Ph.D., David G. Tse, MD, Thomas D. Wynne, MD.
The authors declare that they have no competing interests.
Availability of data and materials
De-identified information will be placed in an IRB-approved (IRB#3535) research repository at the VA Portland Health Care System at the conclusion of the overall project. These data will be available to all researchers upon an approved request to the author.
Consent for publication
Ethics approval and consent to participate
All subjects provided written informed consent to participate and this study was conducted according to all relevant ethical and regulatory guidelines. The Joint Institutional Review Board of the VA Portland Health Care System and OHSU (#10340), and the Legacy IRB, approved this study.
This study and CGS are supported by an award from the Radiation Oncology Institute (#ROI2013-915, Radiation Therapy & Patient-Centered Outcomes among Lung Cancer Patients). It was also supported by resources from the VA Portland Health Care System, Portland, Oregon. CGS was supported by a VA HSR&D Career Development Award (CDA 09-025) while the current study was ongoing. The Department of Veterans Affairs did not have a role in the conduct of the study, in the collection, management, analysis, interpretation of data, or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the US Government.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Golden, S.E., Thomas, C.R., Deffebach, M.E. et al. “It wasn’t as bad as I thought it would be”: a qualitative study of early stage non-small cell lung cancer patients after treatment. BMC Res Notes 10, 642 (2017) doi:10.1186/s13104-017-2956-3
- Thoracic diseases
- Patient-centered outcomes